Evidence map›Paper›PMID 42742287›Full record

ArticleAnnals of neurology2026

Neutrophil Extracellular Traps Block Fibrinolysis in Ischemic Stroke.

Mialitiana Solo Nomenjanahary, Jean-Philippe Desilles, Fatima Zemali, Astride Perrot, Lucas Di Meglio, Sara Zalghout, Jéromine Fasille, Jérémy Neel, Stéphane Loyau, Julien Labreuche and 12 more

Abstract read
In one paragraph

Article in Annals of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Mialitiana Solo NomenjanaharyUniversité Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France.
Jean-Philippe DesillesUniversité Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France.
Fatima ZemaliUniversité Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France.
Astride PerrotUniversité Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France.
Lucas Di MeglioUniversité Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France.
Sara ZalghoutUniversité Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France.
Jéromine FasilleUniversité Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France.
Jérémy NeelUniversité Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France.
Stéphane LoyauUniversité Paris Cité, Inserm, UMRS-1148, Laboratory for Vascular Translational Science, Paris, France.
Julien LabreucheDepartment of Biostatistics, CHU Lille, Lille, France.
Marie-Charlotte BourrienneUniversité Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France.
Dorothée FailleUniversité Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France.ORCID https://orcid.org/0000-0003-4414-739X
François DelvoyeBiological Resource Center and Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France.
Véronique OllivierUniversité Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France.
Sébastien DupontUniversité Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France.
Jasmina RogozarskiUniversité Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France.
Nahida Brikci-NigassaBiological Resource Center and Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France.
Robert L MedcalfMonash University Department of Medicine, Australian Center for Blood Diseases, Monash University, Clayton, Australia.
Nadine AjzenbergUniversité Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France.
Mikael MazighiUniversité Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France.
Benoît Ho-Tin-NoéUniversité Paris Cité, INSERM, Optimisation Thérapeutique en Neuropharmacologie OTEN U1144, Paris, France.ORCID https://orcid.org/0000-0002-7428-1760
compoCLOT Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesIntravenous thrombolysis (IVT) failure in acute ischemic stroke (AIS) is frequent, but its causes remain elusive. We investigated whether biologically relevant intrathrombus concentrations of tissue plasminogen activator (tPA) were achieved in failed IVT and whether neutrophil extracellular traps (NETs) contributed to this therapeutic failure.

methodsIn this monocenter cohort study, 205 thrombi from AIS patients were analyzed. A total of 83 of these thrombi were compared for tPA content and 53 for their susceptibility to ex vivo thrombolysis according to IVT status. An additional subset of 69 AIS thrombi was used to decipher if and how NETs interfere with intrathrombus fibrinolysis.

resultsThrombi from IVT patients contained twice as much tPA than those from no-IVT patients (p < 0.0001). Plasminogen and tPA in AIS thrombi were associated with fibrin, leukocytes, and NETs. Although ex vivo addition of plasminogen did not cause lysis of either no-IVT or IVT thrombi, combining plasminogen with deoxyribonuclease 1 (DNase 1) helped translate the increased tPA content of IVT thrombi into increased thrombolysis. We further show that DNase 1 enables tPA- and plasmin-mediated thrombolysis by eliminating fibrinolysis inhibitors from AIS thrombi.

interpretationThese results indicate that intrathrombus tPA concentrations reached in failed IVT bear a therapeutic potential that is impaired by NETs, which favor intrathrombus retention of fibrinolysis inhibitors and may limit the availability of tPA and plasminogen for fibrinolysis. Our results stress the interest of DNase 1 to enhance the efficacy of current IVT tPA regimens. ANN NEUROL 2026;100:964-978.

Indexed as

Extracellular TrapsFibrinolysisFibrinolytic AgentsIschemic StrokeNeutrophilsTissue Plasminogen ActivatorAgedAged, 80 and overBrain IschemiaCohort StudiesFemaleHumansMaleMiddle AgedPlasminogenThrombolytic TherapyFibrinolytic AgentsPlasminogenTissue Plasminogen Activator

Identifiers

PMID42742287
PMCPMC13688063

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.